Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
2600 Kelly Road
Warrington
Pennsylvania
18976
United States
Tel: 215-488-9300
Fax: 215-488-9301
Website: http://www.discoverylabs.com/
366 articles with Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
-
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock
5/16/2022
Windtree Therapeutics, Inc. announced management will host a conference call and webcast to discuss its istaroxime Phase 2 study in early cardiogenic shock patients following the late-breaker presentation of the data at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain on May 23, 2022.
-
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
5/5/2022
Windtree Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided key business updates.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
4/20/2022
Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced a late-breaker presentation at the upcoming European Society of Cardiology Heart Failure Conference taking place on May 21-24, 2022 in Madrid, Spain.
-
New data unveiled by Windtree Therapeutics shows significant promise in heart failure patients who have deteriorated into cardiogenic shock.
-
Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic ShockIstaroxime significantly improved the systolic blood pressure profile
4/20/2022
Windtree Therapeutics, Inc. today announced positive primary results with istaroxime in rapidly raising systolic blood pressure, the critical clinical objective in treating patients in cardiogenic shock.
-
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
3/31/2022
Windtree Therapeutics, Inc., a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that Craig Fraser, President and Chief Executive Officer, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
3/31/2022
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided key business updates.
-
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
3/22/2022
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced results from its Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury.
-
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic ShockOn track for top-line data in April 2022
3/15/2022
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.
-
Windtree to Present at Oppenheimer’s 32nd Annual Healthcare Conference
3/10/2022
Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time.
-
It was a relatively quiet week for clinical trial announcements. Here’s a look.
-
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress SyndromeData anticipated in first quarter 2022
2/1/2022
Windtree Therapeutics, Inc. today announced it has completed enrollment in its Phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS).
-
Biopharma Executive Perspectives on 2022
1/10/2022
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade. -
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
12/15/2021
Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for the treatment of acute heart failure.
-
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation
11/22/2021
Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients.
-
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
11/10/2021
Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the third quarter ended September 30, 2021 and provided key business updates.
-
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime PatentAnticipated New Patent Will Provide Intellectual Property Protection Until Late 2039
10/25/2021
Windtree Therapeutics, Inc. today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of new patent claims for istaroxime administration.
-
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock Tuesday, October 19th @ 8:00 am Eastern Time
10/14/2021
Windtree Therapeutics, Inc. today announced that on Tuesday, October 19, 2021 at 8:00 am Eastern Time it will host a Key Opinion Leader (KOL) webinar on istaroxime for the treatment of acute heart failure and the upcoming data in early cardiogenic shock.
-
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results
10/12/2021
Windtree Therapeutics, Inc. today announced the results of a US physician survey and an assessment of worldwide total market value for cardiogenic shock.